Oscar Parodi Ortiz de Villate, MD
Pulmonary Disease · Warren, MINPI 1699985689
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,049 of the $50,992 with a category attached, or 86.4%. GSK accounts for 61.3% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $36,204, more than ten times the $338 reported in 2019. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $386.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$31K
- Sanofi$17K
- AstraZeneca$524
- Boehringer Ingelheim$367
- Insmed, Inc.$219
- Grifols USA, LLC$211
- plus $992 from 13 others
Across 158 payments — averaging $6594.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$759K
- Boehringer Ingelheim$133K
- GSK$117K
- AstraZeneca$17K
- Boehringer Ingelheim International GmbH$15K
What the payments were for
- Consulting fees$1,8364%
- Speaking & faculty fees$44,04986%
- Travel & lodging$9732%
- Food & beverage$4,0398%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 59 | $31,273 |
| Sanofi | 14 | $17,405 |
| AstraZeneca | 13 | $524 |
| Boehringer Ingelheim | 8 | $367 |
| Insmed, Inc. | 5 | $219 |
| Grifols USA, LLC | 6 | $211 |
| Pulmonx Corporation | 2 | $173 |
| Mylan Specialty L.p. | 6 | $148 |
| Amgen | 4 | $121 |
| Regeneron Healthcare Solutions, Inc. | 4 | $105 |
| Acclarent, Inc | 1 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Abiomed | 1 | $81 |
| Verona Pharma, Inc. | 2 | $38 |
| Viatris Specialty LLC | 1 | $35 |
| Chiesi USA, Inc. | 2 | $34 |
| Regeneron | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$30,715
- DUPIXENT$15,475
- CHARTIS CATHETER$146
- ZEPHYR DELIVERY CATHETER$146
- ZEPHYR ENDOBRONCHIAL VALVE$146
- PULMONX CHARTIS TABLET CONSOLE$146
- Arikayce$133
- TEZSPIRE$125
- AIRSUPRA$121
- OFEV$121
- ACCLARENT NAVWIRE Sinus Navigation Guidewire$103
How this compares
$50,992 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 51 | $176,004 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 158 | $149,298 |
| Dupixent PenDupilumab | 16 | $61,458 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $16,446 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $12,187 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,895 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $11,588 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $9,928 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,847 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 109 | $4,294 |
| Ventolin HfaAlbuterol Sulfate | 49 | $3,478 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $3,468 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,902 |
| Fluticasone Propionate | 48 | $1,206 |
| Omeprazole | 11 | $454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $31,273 | $363,265272 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat | $367 | $20,03429 claims |
| AstraZenecaBreztri Aerosphere | $524 | $11,89517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Warren
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
- Daniel MaxwellAlpena$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.